Q3 FY2025 · ended Sep 30, 2025 · Revenue $65,625, +108.3% YoY · Filed Nov 14, 2025
Zivo Bioscience, Inc. (ZIVO) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In Q3 of fiscal 2025, the quarter ended Sep 30, 2025, it reported revenue of $65,625 and a net loss of $1.0 million. As of Sep 30, 2025 it held $57,222 in cash and investments and $285,837 in total debt.
Revenue
$65,625
+108.3% vs year-ago quarter
Net income
$-1.03M
+54.5% vs year-ago quarter
Operating cash flow
$-266,556
+75.4% vs year-ago quarter
Free cash flow
—
EPS
$-0.27
+37.2% vs prior quarter
Dividend per share
None
Shares outstanding
3.89M
+9.7% vs year-ago quarter
Net cash
$-228,615
Q3 FY2025
Operating margin
-4045.7%
TTM
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ZIVO (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Bloomfield Hills, MI
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1101026
- Former names
- HEALTH ENHANCEMENT PRODUCTS INC (until Oct 16, 2014); WESTERN GLORY HOLE INC (until Jan 26, 2004)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
Q1 FY2025 Mar 31, 2025 |
Q4 FY2024 Dec 31, 2024 |
Q3 FY2024 Sep 30, 2024 |
|---|---|---|---|---|---|
| Revenue | $65,625 | $53,400 | $0 | $90,000 | $31,500 |
| Operating income | -$1.0M | -$1.6M | -$4.2M | -$1.6M | -$2.3M |
| Net income | -$1.0M | -$1.6M | -$4.2M | -$1.6M | -$2.3M |
| Diluted EPS | -$0.27 | -$0.43 | -$1.12 | — | — |
| Operating cash flow | -$266,556 | -$476,410 | -$1.4M | -$905,722 | -$1.1M |
| Total assets | $559,452 | $703,327 | $1.3M | $1.6M | $495,587 |
| Total liabilities | $3.8M | $3.2M | $2.9M | $2.2M | $2.6M |
| Stockholders' equity | -$3.3M | -$2.5M | -$1.6M | -$514,898 | -$2.1M |
| Cash and investments | $57,222 | $9,823 | $517,189 | $1.5M | $159,403 |
| Total debt | $285,837 | $300,742 | $315,247 | $0 | $22,027 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Mar 30, 2026 | Mar 26, 2026 |
| 8-K |
Current report
Officer or director change
|
Dec 23, 2025 | Dec 19, 2025 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 10, 2025 | Sep 10, 2025 |
| 8-K |
Current report
Officer or director change
|
Aug 18, 2025 | Aug 12, 2025 |
| 10-Q | Quarterly report | Aug 14, 2025 | Jun 30, 2025 |
All 757 Zivo Bioscience, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.